This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rapamune

Pfizer Inc.

Drug Names(s): sirolimus

Description: Sirolimus (Rapamune) is an immunosuppressive agent previously known as rapamycin. It has been under development for more than 20 years before it gained FDA approval on September 15th 1999. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus found in the soil of Easter Island. Structurally, sirolimus resembles tacrolimus and binds to the same intracellular binding protein or immunophilin known as FKBP-12. However, sirolimus has a novel mechanism of action. Whereas tacrolimus and cyclosporine block lymphokine (e.g., IL2) gene transcription , sirolimus acts later to blocks IL2-dependent T lymphocyte proliferation and the stimulation caused by cross-linkage of CD28, possibly by blocking activation of a kinase referred to as mammalian target of rapamycin or mTOR, a serine-threonine kinase that is important for cell cycle progression. Therefore, sirolimus is believed to act in synergy with cyclosporine (or tacrolimus) in suppressing the immune system.

Deal Structure: Rapamune was originally developed by Wyeth using Elan Drug Technologies' NanoCrystal technology. Elan receives manufacturing revenue from production of Rapamune tablets.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.

Elan and Alkermes
In May 2011, Alkermes and Elan announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million. Alkermes and EDT will be combined under a new holding company incorporated in Ireland. This newly created company will be named Alkermes plc. In September 2011, Alkermes and Elan announced...See full deal structure in Biomedtracker

Partners: Alkermes plc


Rapamune News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug